Dr. Sofya Pintova, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York at Buffalo School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 158
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2008Medical school: State University of New York at Buffalo School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 261741 -
Hematology & Oncology Physician
NY license 261741
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
- Mount Sinai Beth Israel New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 158
- Services billed
- 598
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 205 | 50 |
| Established patient office or other outpatient visit, 30-39 minutes | 200 | 90 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 33 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 25 | 25 |
| Advance care planning, first 30 minutes | 18 | 16 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in New York, NY | 43 |
| Famotidine Other prescribers in New York, NY | 43 |
| Imatinib Mesylate | 38 |
| Ondansetron Odt (ondansetron) Other prescribers in New York, NY | 33 |
| Loperamide (loperamide hcl) Other prescribers in New York, NY | 30 |
| Levothyroxine Sodium Other prescribers in New York, NY | 27 |
| Mirtazapine Other prescribers in New York, NY | 21 |
| Lonsurf (trifluridine/tipiracil hcl) | 20 |
| Anastrozole Other prescribers in New York, NY | 17 |
| Lidocaine-Prilocaine (lidocaine/prilocaine) Other prescribers in New York, NY | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 10 payments worth $383 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $221 |
|---|---|
| Beone Medicines USA, Inc. | $72.20 |
| Astellas Pharma US Inc | $52.35 |
| Bayer HealthCare Pharmaceuticals Inc. | $21.85 |
| Daiichi Sankyo Inc. | $16.06 |
| Food and Beverage | $383 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $252,532 in research payments for these studies, mostly to the institutions running them.
- A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors
Chugai Pharmaceutical Co., Ltd. - RO7566802 ATEZOLIZUMAB in Solid Tumors
Genentech, Inc. - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.